






Hematology, Oncology & Blood & Marrow Transplant for NPs & PAs


PHARMACOLOGY CONTENT







Select presentations will contain pharmacology content as noted in the program. Identified presentations represent approximately 6.0 hours of pharmacology content.

Saturday, August 19, 2017	
7:00 a.m.	Breakfast
7:45 a.m.	Welcome and Pre-test <i>Amber B. Koehler, P.A.-C., Darci L. Zblewski, APRN, C.N.P.</i>
General Session 1: Hematology	
8:00 a.m.	Keynote Speaker <i>Angela L. Fink, APRN, C.N.P.</i>
8:30 a.m.	Break
8:35 a.m. 	Updates in Lymphoma <i>Robin R. Klebig, APRN, C.N.P.</i> Objectives: <ul style="list-style-type: none"> Recall basic difference in Hodgkin/non Hodgkin lymphoma Be familiar with targets of new therapies Name at least one new FDA approved indication for lymphoma Apply revised staging and response criteria when using PET-CT in lymphoma Appreciate implications of PET adapted therapy Be aware of new WHO classification of lymphomas
9:05 a.m. 	Updates in Multiple Myeloma <i>Yi (Yi Lisa) L. Hwa, APRN, C.N.P., D.N.P.</i> Objectives: <ul style="list-style-type: none"> Discuss the latest advances in MM management <ul style="list-style-type: none"> New definition Updated staging system Revised response criteria Treatment updates <ul style="list-style-type: none"> Recommendations from NCCN guidelines Apply mSMART risk stratification in selecting therapy Focus on initial therapy for newly diagnosed disease
9:35 a.m. 	CAR-T Cell Therapy in Lymphoma, Leukemia and Multiple Myeloma <i>Jessica L. Shelly, APRN, C.N.P.</i> Objectives: <ul style="list-style-type: none"> CART-cell mechanism Present data in hematologic malignancies <ul style="list-style-type: none"> Leukemia Lymphoma Multiple Myeloma

	<ul style="list-style-type: none"> Clinical Indications
10:05 a.m.	<p>Panel Q & A</p> <p><i>Angela L. Fink, APRN, C.N.P., Yi (Yi Lisa) L. Hwa, APRN, C.N.P., D.N.P., Robin R. Klebig, APRN, C.N.P., Jessica L. Shelly, APRN, C.N.P.</i></p>
10:25 a.m.	Refreshment Break
Panel: Palliative Care	
10:40 a.m. 	<p>Hospice versus Palliative care: Which One and When Is the Right Time? <i>Timothy J. Moynihan, M.D.</i></p> <p>Objectives:</p> <ul style="list-style-type: none"> Understand the difference between hospice and palliative care Recognize when to make referrals to hospice and palliative care Understand limitations to each program Be able to communicate to patients and families the benefits of each program. <p>Complementary Medicine: “Complementing” Cancer Care <i>Kelly J. Christensen, P.A.-C.</i></p> <p>Objectives:</p> <ul style="list-style-type: none"> To better understand what complementary medicine is. Better understand how these therapies can be used to manage symptoms. Spark thought/questions. Promote a desire to look into complementary options in your own local communities. <p>Pain Control: Update on ASCO Guidelines <i>Jacob J. Strand, M.D.</i></p>
12:10 p.m.	<p>Lunch</p> <p>Lunchtime Topical Networking Tables with Clinical Expert Faculty</p> <ol style="list-style-type: none"> Palliative Care – <i>Kelly J. Christensen, P.A.-C.</i> CAR-T – <i>Yi Lin, M.D., Ph.D.</i> Fellowship – <i>Yi Lisa Hwa, APRN, C.N.P., D.N.P. and Jessica L. Shelly, APRN, C.N.P.</i> BMT Allo Transplant Versus Auto Transplant – <i>Kimberly L. Gollbach, APRN, M.S.N.</i> BMT GVHD - <i>Brenda L. Frye, P.A.-C.</i> Breast Cancer – <i>Deanne R. Smith, A.PRN, C.N.P., M.S.N.</i> NP/PA Career Development: Research and Publications—<i>Lisa A. Kottschade, APRN, C.N.P.</i>
General Session 2: Oncology	
1:00 p.m. 	<p>Delayed Skin Changes after Breast Radiation: Benign or Malignant? <i>Deanne R. Smith, APRN, C.N.P., M.S.N.</i></p> <p>Objectives:</p>

	<ul style="list-style-type: none"> Name several types of skin changes that may occur after breast radiation Describe breast/chest wall skin findings that may indicate malignancy, particularly angiosarcoma Identify strategies for monitoring skin changes
1:30 p.m. 	<p>Advances in Targeted Therapies: The Role for EGFR and ALK TKIs in Non-Small Cell Lung Cancer <i>Erin L. Deering, APRN, C.N.P.</i> Objectives:</p> <ul style="list-style-type: none"> Explain the current treatment paradigm for patients with EGFR- and ALK-mutated non-small cell lung cancer (NSCLC), with an understanding of the cellular pathophysiology Outline the different classes of targeted therapies and describe the mechanism of action of each Review class-related side effects Identify and implement strategies to mitigate treatment-related side effects associated with EGFR and ALK tyrosine kinase inhibitors (TKIs)
2:00 p.m.	<p>Colorectal Cancer Updates <i>Rachel A. Eiring, P.A.-C.</i></p>
2:30 p.m.	<p>Panel Q & A <i>Erin L. Deering, APRN, C.N.P., Rachel A. Eiring, P.A.-C., Deanne R. Smith, APRN, C.N.P., M.S.N.</i></p>
2:50 p.m.	Refreshment Break
General Session 3: Bone Marrow Transplant	
3:00 p.m.	<p>Allogeneic versus Autologous Blood and Marrow Transplant: What is the Difference? <i>Kimberly L. Gollbach, APRN, D.N.P., C.N.P.</i></p>
3:30 p.m.	<p>Graft Versus Host Disease <i>Brenda L. Frye, P.A.-C.</i></p>
4:00 p.m.	<p>Social Issues and Financial Impact of Blood and Marrow Transplant <i>Brady R. Voigt, L.I.C.S.W., M.S.W.</i></p>
4:30 p.m.	<p>Panel Q & A <i>Brenda L. Frye, P.A.-C., Kimberly L. Gollbach, APRN, D.N.P., C.N.P., Brady R. Voigt, L.I.C.S.W., M.S.W.</i></p>
4:50 p.m.	Adjourn
6:00 p.m.	<p>Reception Hage Atrium</p>

Sunday, August 20, 2017	
7:30 a.m.	Breakfast
General Session 4: Supportive Care	
8:00 a.m. 	Immunotherapy: What the Clinician Needs to Know <i>Adrienne N. Nedved, Pharm.D., M.P.A., BCOP</i> Objectives: <ul style="list-style-type: none"> • Describe the overall concept of immunotherapy • Recall specific immunotherapy agents utilized in oncology & hematology • Identify and distinguish signs & symptoms of immune related adverse events (irAEs) secondary to immunotherapy • Determine appropriate treatment strategies for the management of irAEs
8:30 a.m. 	Chemotherapy Induced Menopause <i>Emily A. Olson, APRN, C.N.P., M.S.N.</i> Objectives: <ul style="list-style-type: none"> • Understand common chemotherapy agents that may induce menopause • Identify age groups most at risk for chemotherapy induced menopause • Identify common physical sequelae of menopause <ul style="list-style-type: none"> • Vasomotor symptoms • Vaginal atrophy and sequelae • Arthralgias • Identify cardiovascular health risks resulting from premature menopause • Develop the ability to provide anticipatory guidance for those facing chemotherapy induced menopause
9:00 a.m. 	Fungal Infections in the Patient with Prolonged Immunosuppression <i>Catherine (Cate) D. Zomok, P.A.-C.</i> Objectives: <ul style="list-style-type: none"> • Be aware of risk factors for invasive fungal disease • Be familiar with the common organisms that cause invasive fungal infections. • Be able to recognize common clinical presentations of invasive fungal infections. • Be able to recognize common radiographic and laboratory findings present in invasive fungal infections. • Be familiar with the antifungal agents and their common adverse effects
9:30 a.m.	Panel Q & A <i>Adrienne N. Nedved, Pharm.D., M.P.A., BCOP, Emily A. Olson, APRN, C.N.P., M.S.N., Catherine (Cate) D. Zomok, P.A.-C.</i>

9:50 a.m.	Refreshment Break
General Session 5	
10:00 a.m.	MDS and World Health Organization Updates on Diagnosis <i>Darci L. Zblewski, APRN, C.N.P.</i>
10:30 a.m.	AML – Evolving Treatments <i>Jennie M. Goble, P.A.-C.</i>
11:00 a.m. 	Management of Hematologic Emergencies <i>Amber B. Koehler, P.A.-C.</i> Objectives: <ul style="list-style-type: none"> • Discuss prevention and management of tumor lysis syndrome <ul style="list-style-type: none"> • Make an informed decision regarding rasburicase administration with respect to timing and dosing • Initiate appropriate workup and initial management of suspected hypercalcemia of malignancy • Initiate appropriate workup and initial management of neutropenic fever <ul style="list-style-type: none"> • Make an informed decision regarding use of vancomycin in choice of empiric antibiotic coverage in neutropenic fever
11:30 a.m.	Panel Q & A <i>Jennie M. Goble, P.A.-C., Amber B. Koehler, P.A.-C., Darci L. Zblewski, APRN, C.N.P.</i>
11:50 a.m.	Lunch Lunchtime Topical Networking Tables with Clinical Expert Faculty <ol style="list-style-type: none"> 1. Oncology – <i>Emily A. Olson, APRN, C.N.P., M.S.N.</i> 2. Immunotherapy – <i>Adrienne N. Nedved, Pharm.D., M.P.A., BCOP</i> 3. Survivorship, Lymphoma – <i>Patricia A. Gerber, APRN, M.S.N., C.N.P.</i> 4. BMT Survivorship – <i>Kimberly J. Langer, APRN., C.N.P., D.N.P.</i> 5. MDS Management – <i>Darci L. Zblewski, APRN., C.N.P.</i>
Survivorship Panel	
12:30 p.m.	BMT Survivorship – <i>Kimberly J. Langer, APRN, C.N.P., D.N.P.</i> Hematology Survivorship – <i>Patricia (Patty) A. Gerber, APRN, M.S.N., C.N.P.</i> Oncology Survivorship – <i>Rachel A. Eiring, P.A.-C.</i> Breast Cancer Survivorship – <i>Jennifer K. Hazelton, APRN, C.N.S.</i>
2:00 p.m.	Looking Ahead
2:45 p.m.	Course Wrap Up & Post-Test
3:00 p.m.	Course Adjourns